Cerebrolysin

Why Researchers Choose Cerebrolysin

Cerebrolysin stands apart from single-target neuropeptides because it is a multi-fraction neurotrophic complex with one of the deepest clinical datasets in the field. The 60mg presentation (6 vials) is studied wherever broad neuroprotective and pro-regenerative signalling is the goal:

• Neurotrophic-factor mimicry across BDNF, NGF, GDNF and NT-3 pathways
• Cognitive-decline and dementia models, including Alzheimer’s disease
• Post-stroke and post-injury neuro-recovery research
• Synaptic plasticity, long-term potentiation and memory-consolidation studies
• Adult neurogenesis and axonal-regeneration investigations

Neurotrophic Mechanism

Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF) and neurotrophin-3 (NT-3) are the core survival and plasticity signals for neurons. They sustain neuronal survival under stress, enable long-term potentiation (LTP) and memory consolidation, support adult neurogenesis in the hippocampal dentate gyrus, and drive axonal regeneration after injury.

The obstacle is delivery. Full-length neurotrophins (BDNF around 27 kDa, NGF around 26 kDa) are too large to cross the blood-brain barrier, so peripheral dosing of the intact proteins produces little meaningful central nervous system effect. Cerebrolysin sidesteps this limitation: its low molecular weight peptide fractions pass the barrier through amino acid and small peptide transporters, then activate TrkB (the BDNF receptor), TrkA (the NGF receptor) and RET (the GDNF co-receptor). The resulting MAPK/ERK, PI3K/Akt and PLC-gamma signalling promotes neuronal survival, synaptic plasticity and neurogenesis.

Key Research Areas

Alzheimer’s disease: Multiple randomised trials and meta-analyses report cognitive benefit in mild-to-moderate AD, including improved ADAS-cog and MMSE scores versus placebo and slower functional decline, with proposed disease-modifying effects linked to reduced amyloid oligomer toxicity and tau phosphorylation.

Acute ischaemic stroke: The multinational CASTA trial and later meta-analyses found improved neurological outcomes when cerebrolysin was given within roughly 24 to 48 hours of stroke onset. Proposed contributors include reduced excitotoxicity through NMDA receptor modulation, anti-apoptotic Akt activation in penumbral neurons, and enhanced axonal sprouting and synaptic reorganisation.

Traumatic brain injury: Work in military and sports-medicine settings points to improved cognitive recovery after head injury.

Cerebrolysin vs Isolated Peptides (Semax, Selank, P21)

Cerebrolysin leads when the priority is the broadest evidence base and multi-pathway coverage. Isolated peptides remain the better fit for mechanism-specific questions.

Administration and Storage

Storage: ready-to-use liquid, no reconstitution required; keep vials at 10-25°C and observe the shelf life on the vial label. In use: administer by intravenous infusion or intramuscular injection (research protocols commonly diluted 10-30 ml in 100 ml saline over 15-20 minutes), and use an opened vial within the same session.

For research purposes only. Not for human consumption.